Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (formerly Selecta Biosciences, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: A clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. The company completed a merger with Old Cartesian Therapeutics in November 2023 and executed a 1-for-30 reverse stock split in April 2024. It currently has no approved products and relies on collaboration revenue and equity financing.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $387 | $6,551 | $39,672 | $17,738 |
| Net Loss | $(24,183) | $(9,002) | $(67,171) | $(42,052) |
| Net Loss Per Share (Basic/Diluted) | $(1.13) | $(1.74) | $(4.61) | $(8.20) |
| Operating Expenses | $17,962 | $19,616 | $56,838 | $67,822 |
| Cash, Cash Equivalents & Restricted Cash | $220,867 (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(681,818) (as of Sept 30, 2024) |
Liquidity: As of September 30, 2024, the company held $219.2 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Volatility: Collaboration revenue dropped to zero in Q3 2024 compared to $6.6 million in Q3 2023 due to the termination of the Astellas agreement and the timing of milestone recognition. However, for the nine months ended Sept 30, 2024, revenue increased 121% to $39.7 million, driven by a $30.0 million milestone payment from Sobi for the SEL-212 program.
- Net Loss Expansion: Net loss for Q3 2024 increased to $24.2 million from $9.0 million in the prior year quarter. This was primarily driven by a $15.1 million expense related to the change in fair value of the Contingent Value Right (CVR) liability.
- Financing Activity: The company raised approximately $130.0 million in gross proceeds in July 2024 via a private placement of common stock and Series B Preferred Stock. Additionally, the remaining Series A Preferred Stock forward contract liability was settled in Q1 2024.
- Restructuring: The company continued to execute a restructuring plan initiated in 2023, resulting in an approximate 90% reduction in headcount. Restructuring expenses for the nine months ended Sept 30, 2024, were $0.8 million.
Guidance, Outlook, and Risks
- Outlook: The company expects to continue incurring significant operating losses as it advances its lead candidate, Descartes-08, into Phase 3 development for myasthenia gravis (MG). No product revenue is expected for the foreseeable future.
- CVR Liability: A significant liability ($410.5 million as of Sept 30, 2024) exists for Contingent Value Rights (CVRs) issued to legacy stockholders. This liability is settled solely through cash flows from the Sobi License and legacy asset monetization. Changes in the fair value of this liability significantly impact reported net loss.
- Material Weakness: Management identified a material weakness in internal controls over financial reporting related to the documentation of assumptions for valuing in-process intangible assets and the CVR obligation. Remediation plans are underway.
- Risks: Key risks include the ability to raise additional capital, the success of clinical trials, regulatory approvals, and the potential dilution of existing shareholders from future equity financings.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $220.9 million cash balance against the projected costs of the Phase 3 trial for Descartes-08 and ongoing R&D.
- CVR Liability Impact: Assess the sensitivity of the $410.5 million CVR liability to changes in the Sobi License milestone payments and discount rates, as this drives non-cash net losses.
- Revenue Recognition: Confirm the timing and probability of future milestone payments from Sobi, which are the primary source of near-term revenue.
- Internal Controls: Monitor the progress of remediation for the identified material weakness regarding valuation documentation.
- Equity Dilution: Track the conversion of outstanding Series A and Series B Preferred Stock into common stock and potential future equity raises.